文献速递肝病

解析肝脏炎症生态系统确定膜联蛋白A1为肝衰竭促炎症消退靶点

Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure.
PubMed 文献 · Hepatology · 2025-06-12

本研究采用单细胞RNA测序、空间转录组测序、批量RNA测序及生物信息学分析,刻画慢加急性肝衰竭(ACLF)肝脏免疫景观。ACLF肝脏中性粒细胞(尤其CCL4+亚群)增多,驻留Kupffer细胞减少,单核细胞分化为TREM2+巨噬细胞呈M1样促炎表型,NK细胞减少且T细胞功能失调。细胞通讯分析发现ANXA1-FPR1轴为T细胞与髓系细胞间关键负反馈通路。ACLF患者血浆及肝内ANXA1水平升高并与疾病严重程度相关。临床前模型中ANXA1肽Ac2-26改善肝功能、减轻炎症并促进巨噬细胞M1向M2极化;体外Ac2-26抑制CCL4介导的单核细胞趋化及M1极化,该效应可被FPR1抑制剂Randialic acid B部分阻断;机制上Ac2-26激活AMPK并抑制mTOR信号。结论提示ANXA1为ACLF潜在治疗靶点。

要点

  • ACLF肝脏中性粒细胞(尤其CCL4+亚群)增多,招募炎症性CD14+S100A9+单核细胞驱动持续炎症。
  • ANXA1-FPR1轴为T细胞与髓系细胞间抑制炎症的负反馈机制,ACLF患者血浆及肝内ANXA1升高且与疾病严重程度相关。
  • 临床前模型中ANXA1肽Ac2-26改善肝功能、减轻炎症并促进巨噬细胞M1向M2极化。

核心结论

  • 本研究提供ACLF全面免疫图谱,并提示ANXA1是纠正免疫失调、改善ACLF结局的潜在治疗靶点。

研究设计与样本

  • 采用单细胞RNA测序、空间转录组测序、批量RNA测序及生物信息学分析,比较ACLF、急性肝衰竭、失代偿期肝硬化与对照肝脏的免疫细胞。
  • 临床前模型及体外实验评估ANXA1肽Ac2-26的作用及FPR1抑制剂Randialic acid B的阻断效应。

主要发现

  • ACLF肝脏中性粒细胞增多,尤其CCL4+亚群,通过招募更多中性粒细胞及炎症性CD14+S100A9+单核细胞驱动未消退炎症。
  • ACLF肝脏驻留Kupffer细胞减少,单核细胞分化为TREM2+巨噬细胞呈M1样促炎表型,加重炎症。
  • ACLF淋巴样细胞显著功能障碍,NK细胞减少,T细胞相对扩增但细胞毒性或促炎细胞因子产生减弱。
  • 细胞通讯分析确定ANXA1-FPR1轴为T细胞与髓系细胞间关键相互作用,作为抑制炎症的负反馈机制。
  • ACLF患者血浆及肝内ANXA1水平升高,与疾病严重程度相关。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) is driven by systemic inflammation and immune dysregulation. This study aims to characterize the immune landscape in ACLF and identify potential therapeutic targets. APPROACH AND RESULTS: We employed single-cell RNA sequencing, vision spatial sequencing, bulk RNA sequencing, and bioinformatics analysis to profile immune cells in ACLF livers compared to acute liver failure, decompensated cirrhosis, and controls. ACLF livers exhibited a distinct immune signature with increased neutrophils, particularly CCL4 + subsets, which drive unresolved inflammation by recruiting additional neutrophils and inflammatory CD14 + S100A9 + monocytes. Resident KCs were reduced, and monocytes differentiated into TREM2 + macrophages with an M1-like pro-inflammatory phenotype, exacerbating inflammation. Additionally, lymphoid cells showed significant dysfunction, with reduced NK cells and relatively expanded T cells exhibiting diminished cytotoxicity or pro-inflammatory cytokine production. Cell-cell communication analysis identified the ANXA1-FPR1 axis as a key interaction between T cells and myeloid cells, serving as a negative feedback mechanism to dampen inflammation. Plasma and hepatic ANXA1 levels were elevated in ACLF patients, correlating with disease severity. In the preclinical model, the ANXA1 peptide Ac2-26 improved liver function, reduced inflammation, and promoted macrophage polarization from M1 to M2. In vitro, Ac2-26 inhibited CCL4-mediated monocyte chemotaxis and M1 polarization, effects partially blocked by the FPR1 inhibitor Randialic acid B. Mechanically, Ac2-26 activated AMPK and inhibited mTOR signaling. CONCLUSIONS: Our findings provide a comprehensive immune profile in ACLF and highlight ANXA1 as a potential therapeutic target for resolving immune dysregulation and improving outcomes in ACLF.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Yu X, Tian W, Bao X, et al. Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure. Hepatology. 2025. PMID: 40560812. doi:10.1097/HEP.0000000000001427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。